Merck to acquire Harpoon Therapeutics for $680M

Merck has struck a deal to buy Harpoon Therapeutics for $680 million, beefing up its oncology pipeline with a portfolio of T cell engagers.

At $23 per share, Merck’s offer comes in at a 100%-plus premium to Harpoon’s closing stock price on Friday — although it’s already surged close to…
Click here to view original post

Advertisement — Advertise with Biotech Networks